Pneumatica Bio provides a high‑throughput, computational platform that predicts the therapeutic function of next‑generation drugs without the need for animal or human trials. By modeling clinical translation pathways, the system identifies promising candidates early, reducing financial risk and accelerating development timelines for rare‑disease and mRNA‑based therapies. Their approach aims to replace trial‑and‑error drug design with data‑driven predictions, helping bring effective treatments to patients faster.
Funding
Funding not disclosed
Founders
Product
Problem
Developing new therapeutics, especially next‑generation modalities like mRNA‑encapsulating lipid nanoparticles, requires a decade‑long, billion‑dollar process with a high failure rate in clinical trials. The reliance on animal and early‑phase human studies creates substantial financial risk and delays the delivery of effective treatments to patients.
Solution
Pneumatica Bio offers a high‑throughput, in‑silico platform that predicts the therapeutic function and clinical translation outcomes of novel drug candidates without conducting animal or human trials. By integrating mechanistic models of pharmacokinetics, biodistribution, and target engagement, the system simulates the entire clinical development pathway, identifying potential failures early. This predictive approach reduces the financial risk of late‑stage trial failures and accelerates the progression from preclinical promise to patient impact, particularly for personalized and rare‑disease therapies.
Target Audience
Primary customers are biotech and pharmaceutical companies developing next‑generation therapeutics such as mRNA‑based drugs, lipid nanoparticle carriers, and other advanced delivery platforms, especially those targeting rare diseases and personalized medicine.
Features
- Scalable computational pipeline that evaluates thousands of candidate formulations per week
- Mechanistic modeling of mRNA‑lipid nanoparticle delivery, including cellular uptake and expression kinetics
- End‑to‑end simulation of clinical trial phases to forecast efficacy, safety, and regulatory success probabilities
- Quantitative risk assessment reports that replace early animal studies and inform go/no‑go decisions
- Integration with existing drug discovery workflows via API and data export tools